Leleu X; Masszi, Tamás; Bahlis NJ; Viterbo L; Baker B; Gimsing P; Maisnar V; Samoilova O; Rosinol L; Langer C; Song K; Izumi T; Cleeland C; Berg D; Lin HM; Zhu YY; Skacel T; Moreau P; Richardson PG
(2018)
TOURMALINE-MM1 is a phase III, randomized, double-blind, placebo-controlled study of ixazomib plus lenalidomide and dexamethasone (IRd) versus placebo-Rd in patients with relapsed/refractory multiple myeloma following 1-3 ...